Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma

T. Tsushima; M. Noda; Y. Nasu; H. Ohmori; A. Yamamoto; H. Takigawa; S. Kagawa; Y. Matsumura; T. Matsumoto; I. Ogawa; A. Kawano; M. Nishi; S. Akazawa; S. Nakamura; K. Y. Akiyama; K. Tatara; Y. Sumiyoshi; Y. Aga; T. Yokota

Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma

T. Tsushima, M. Noda, Y. Nasu, H. Ohmori, A. Yamamoto, H. Takigawa, S. Kagawa, Y. Matsumura, T. Matsumoto, I. Ogawa, A. Kawano, M. Nishi, S. Akazawa, S. Nakamura, K. Y. Akiyama, K. Tatara, Y. Sumiyoshi, Y. Aga, T. Yokota

Research output: Contribution to journal › Article › peer-review

Abstract

A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 10⁶ units per body, per day, administered intramuscularly, 5-FU at 500 mg/m² per day, administered intravenously (days 1 to 5) and MMC 2 mg/m² per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).

Original language	English
Pages (from-to)	986-991
Number of pages	6
Journal	Nishinihon Journal of Urology
Volume	56
Issue number	9
Publication status	Published - 1994

Keywords

5-fluorouracil
interferon-α
mitomycin C
renal cell carcinoma

ASJC Scopus subject areas

Urology

Cite this

Tsushima, T., Noda, M., Nasu, Y., Ohmori, H., Yamamoto, A., Takigawa, H., Kagawa, S., Matsumura, Y., Matsumoto, T., Ogawa, I., Kawano, A., Nishi, M., Akazawa, S., Nakamura, S., Akiyama, K. Y., Tatara, K., Sumiyoshi, Y., Aga, Y., & Yokota, T. (1994). Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma. Nishinihon Journal of Urology, 56(9), 986-991.

Tsushima, T, Noda, M, Nasu, Y, Ohmori, H, Yamamoto, A, Takigawa, H, Kagawa, S, Matsumura, Y, Matsumoto, T, Ogawa, I, Kawano, A, Nishi, M, Akazawa, S, Nakamura, S, Akiyama, KY, Tatara, K, Sumiyoshi, Y, Aga, Y & Yokota, T 1994, 'Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma', Nishinihon Journal of Urology, vol. 56, no. 9, pp. 986-991.

@article{a20feff4439c48deb152689f1a00605a,

title = "Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma",

abstract = "A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).",

keywords = "5-fluorouracil, interferon-α, mitomycin C, renal cell carcinoma",

author = "T. Tsushima and M. Noda and Y. Nasu and H. Ohmori and A. Yamamoto and H. Takigawa and S. Kagawa and Y. Matsumura and T. Matsumoto and I. Ogawa and A. Kawano and M. Nishi and S. Akazawa and S. Nakamura and Akiyama, {K. Y.} and K. Tatara and Y. Sumiyoshi and Y. Aga and T. Yokota",

year = "1994",

language = "English",

volume = "56",

pages = "986--991",

journal = "Nishinihon Journal of Urology",

issn = "0029-0726",

publisher = "Kyushu University, Faculty of Science",

number = "9",

}

TY - JOUR

T1 - Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma

AU - Tsushima, T.

AU - Noda, M.

AU - Nasu, Y.

AU - Ohmori, H.

AU - Yamamoto, A.

AU - Takigawa, H.

AU - Kagawa, S.

AU - Matsumura, Y.

AU - Matsumoto, T.

AU - Ogawa, I.

AU - Kawano, A.

AU - Nishi, M.

AU - Akazawa, S.

AU - Nakamura, S.

AU - Akiyama, K. Y.

AU - Tatara, K.

AU - Sumiyoshi, Y.

AU - Aga, Y.

AU - Yokota, T.

PY - 1994

Y1 - 1994

N2 - A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).

AB - A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).

KW - 5-fluorouracil

KW - interferon-α

KW - mitomycin C

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027940223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027940223&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027940223

SN - 0029-0726

VL - 56

SP - 986

EP - 991

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

IS - 9

ER -

Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this